Ibrutinib

Lymphoid Leukemia

Loxo Oncology, Inc.Small moleculePhase 4 / ApprovedActive

BBB

72/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 61/ 100
Competitive Position: 89/ 100

Competitive context

12 Active assets in the Lymphoid Leukemia cohort.

Asset / Sponsor	Phase	Rating
Fludarabine Dartmouth-Hitchcock Medical Center	Phase 4	BBB
Busulfanum Dartmouth-Hitchcock Medical Center	Phase 4	BB
Pirtobrutinib Loxo Oncology, Inc.	Phase 3	BB
Lenalidomide University of Wisconsin, Madison	Phase 2	BB
Dexasone St. Jude Children's Research Hospital	Phase 2	BB

View all 50 →

Same molecule, other indications

Ibrutinib is also rated in:

B-cell chronic lymphocytic leukemiaActive

BB

Indicative · Phase 4

70 / 100

Waldenstrom macroglobulinemiaActive

BB

Indicative · Phase 4

70 / 100

chronic lymphocytic leukemia/small lymphocytic lymphomaActive

BB

Indicative · Phase 3

68 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.